Cargando…

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4–7. Recent responder subgroup analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Albrecht, Philipp, Bjørnå, Ingrid Kristine, Brassat, David, Farrell, Rachel, Feys, Peter, Hobart, Jeremy, Hupperts, Raymond, Linnebank, Michael, Magdič, Jožef, Oreja-Guevara, Celia, Pozzilli, Carlo, Salgado, Antonio Vasco, Ziemssen, Tjalf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174649/ https://www.ncbi.nlm.nih.gov/pubmed/30305850 http://dx.doi.org/10.1177/1756286418803248

Ejemplares similares

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
por: Hobart, Jeremy, et al.
Publicado: (2018)

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE
por: Hupperts, Raymond, et al.
Publicado: (2022)

Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial
por: Hupperts, Raymond, et al.
Publicado: (2016)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Improving patient–physician dialog: commentary on the results of the MS Choices survey
por: Lugaresi, Alessandra, et al.
Publicado: (2012)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine
por: Sola-Valls, Núria, et al.
Publicado: (2018)

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report
por: Müller, Mona Klara Ros, et al.
Publicado: (2022)

Fampridine and quality of life in individuals with multiple sclerosis
por: Sagawa, Yoshimasa, et al.
Publicado: (2016)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases
por: Prugger, Michael, et al.
Publicado: (2013)

Prolonged-Release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: A Pilot, Double-Blind, Randomized, Placebo-Controlled Study
por: Jacques, François, et al.
Publicado: (2018)

Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study
por: Mamoei, Sepehr, et al.
Publicado: (2021)

Diagnosis and treatment of progressive multiple sclerosis: A position paper
por: Pozzilli, Carlo, et al.
Publicado: (2022)

Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool
por: Hobart, Jeremy, et al.
Publicado: (2022)

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis
por: Zeller, D, et al.
Publicado: (2014)

Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function
por: Rabadi, Meheroz H., et al.
Publicado: (2013)

Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients
por: Moghadasi, Abdorreza Naser
Publicado: (2021)

Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel
por: Oreja-Guevara, Celia, et al.
Publicado: (2023)

A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study
por: Mitsikostas, Dimos D., et al.
Publicado: (2021)

Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
por: Yamout, Bassem I, et al.
Publicado: (2022)

Improving Digital Patient Care: Lessons Learned from Patient-Reported and Expert-Reported Experience Measures for the Clinical Practice of Multidimensional Walking Assessment
por: Scholz, Maria, et al.
Publicado: (2021)

Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2023)

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
por: Berger, Thomas, et al.
Publicado: (2016)

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine)
por: Keune, Philipp M., et al.
Publicado: (2015)

Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment
por: Ahdab, Rechdi, et al.
Publicado: (2019)

Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
por: Castelnovo, Giovanni, et al.
Publicado: (2021)

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
por: Rieckmann, Peter, et al.
Publicado: (2021)

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
por: Centonze, Diego, et al.
Publicado: (2021)

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial
por: Kanhai, Kawita M. S., et al.
Publicado: (2019)

Reputational assets for local political leadership
por: Bjørnå, Hilde
Publicado: (2021)

Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide
por: Van Wijmeersch, Bart, et al.
Publicado: (2022)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_549e6d5lujltun45h0fkdkvluk